<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11552">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956551</url>
  </required_header>
  <id_info>
    <org_study_id>SKLB1608</org_study_id>
    <nct_id>NCT02956551</nct_id>
  </id_info>
  <brief_title>Neoantigen-primed Dendritic Cells (DC)- Pre-activated T (PreT) Cell Therapy for Refractory Non-small Cell Lung Cancer</brief_title>
  <acronym>SKLB1608</acronym>
  <official_title>Neoantigen-primed DC-PreT Cell Therapy for Refractory Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to the test the efficacy and safety of neoantigen-primed T cell therapy
      for refractory non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with pathological confirmed non-small cell lung cancer with no standard treatment
      are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of
      targeted therapy where applicable. This is a prospective exploratory trial. Patients'
      rebiopsy tumor tissues are subsequent to whole exosome sequencing and possible neoantigens
      are identified. DC is in vitro primed with synthesized peptides. Patients are treated with
      DC-primed T cells. Both adverse events and responses are recorded.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>3 months after the last administration of cells</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of particiants with objective responses as assayed by RECIST 1.1</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>cell_therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tumor neoantigen primed DC-PreT cells are administrated, 3-days interval, totally 3 times</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T cells</intervention_name>
    <description>intravenous administration</description>
    <arm_group_label>cell_therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathologically confirmed non-small cell lung cancer

          -  failed in previous standard chemotherapy and targeted therapy

          -  anticipated life time &gt; 3month

          -  Karnofsky performance status 0-1

          -  rehabilitate from previous therapy

          -  adequate organ functions

        Exclusion Criteria:

          -  mixed histological types

          -  tumor emergency

          -  abnormal coagulation condition

          -  contagious diseases, such as HBV, HCV, HIV, TB infection

          -  concomitant tumors

          -  immunological co-morbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen-Yu Ding, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhen-Yu Ding, Prof</last_name>
    <email>dingzhenyu@scu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>China West Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 3, 2016</lastchanged_date>
  <firstreceived_date>November 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Zhen-Yu Ding</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>advanced non-small cell lung cancer</keyword>
  <keyword>cell based therapy</keyword>
  <keyword>safety</keyword>
  <keyword>clinical efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
